A better screening for a better care

Our On-the-Spot testing solution

O

In our dynamic world, a better syndromic Point-of-Care testing is key to improve linkage to care. It enables swift diagnosis, timely treatment, and enhanced patient outcomes. Syndromic screening is a vital tool in controlling infectious diseases, reducing spread, and preventing outbreaks. However, it is often limited to lab settings and rarely available at the Point-of-Care. Beyond patient convenience, it optimizes resource use, ensuring healthcare remains accessible and fair to all.

MagIA diagnostics, driven by these ideals, is pioneering an innovative on-the-spot system, the M-for-Screen. It is fusing an easy-to-use cartridge approach with an easy-to-deploy analyzer, all dedicated to raising the bar at the point-of need.

Key advantages

Innovative rapid and portable panel testing

Simple: 50 µl blood tested on an intuitive system

Portable: True On-the-Spot testing

Multiplexed: Up to 8 parameters at once

Safe: Objective results – embedded internal control

Fast: Results in 12 to 18 minutes ( after loading of 1 or 2 cartridges)

Flexible: Capillary or veinous blood, serum, plasma

Generic: One generic platform, adaptable to all immunoassays

Simple: 50 µl blood tested on an intuitive system

Portable: True On-the-Spot testing

Multiplexed: Up to 8 parameters at once

Safe: Objective results – embeded internal control

Fast: Results in 12 to 18 minutes (after loading of 1 or 2 cartridges)

Flexible: Capillary or veinous blood, serum, plasma

Generic: One generic platform / Adaptable to all immunoassays

Our solution

A combination of single use cartridges and a portable instrument for the syndromic Point-of-Care testing

MagIA analyzer

Easy to deploy: Our key for a flexible and simple solution

Our M for screen analyzer presents many benefits:

  • Portability: A system weight below 3 kg. Get it done wherever needed
  • Autonomy: 2 removable batteries for up to 8 hours off the grid
  • Modularity: Analyze either 1 or 2 cartridges in parallel
  • Objectivity: unambiguous and qualitative results

M for screen can be upgraded using the following accessories:

  • Mini-printer: for patient results printing
  • Hand-held scanner: for patient identification

MagIA test

Easy to use: From a single drop of blood

Each MagIA test is composed of a cartridge, a lancet, a pipette and a ready to use MagIA diluent dropper bottle.

How does it work?

  1. Collect 50 µl capillary blood using lancet and pipette
  2. Dilute blood in the dropper bottle
  3. Fill the cartridge
  4. Insert the cartridge in MagIA analyzer
  5. Get results in 12 minutes

MagIA test

Easy to use: From a single drop of blood

Each MagIA test is composed of a cartridge, a lancet, a pipette and a ready to use MagIA diluent dropper bottle.

How does it work?

  1. Collect 50 µl capillary blood using lancet and pipette
  2. Dilute blood in the dropper bottle
  3. Fill the cartridge
  4. Insert the cartridge in MagIA analyzer
  5. Get results in 12 minutes

MagIA IBC

Syndromic screening of HIV, Hepatitis B & C

As per the World Health Organization (WHO), approximately 400 million individuals worldwide are currently infected with HIV and Viral Hepatitis. Each year, there are 4.5 million new infections and 1.8 million fatalities attributed to these diseases. HIV and Viral Hepatitis are pressing global health concerns.

In Europe, there are over 80 million people at risk to be infected. HIV is regularly tested on the spot, whereas Viral Hepatitis testing is usually not included, as most syndromic approaches are limited to laboratory assays and not conducted at the Point-of-Care.  Consequently, HIV cases are well-diagnosed, but awareness of viral Hepatitis status remains low, with less than 20% of those infected being aware of their status.

This highlights the need for a combined screening approach at the Point-of-Care to better manage the epidemics and link key populations to care.

In response to this demand, we have developed the MagIA IBC test. This specialized test is designed for the detection of active infections and specifically screens for anti-HIV, anti-HCV, and HBsAg in capillary blood samples.

Therefore, MagIA IBC test enables the simultaneous detection of HIV, Hepatitis B & C infections. Swift and accurate identification of the presence or absence of these pathogens supports timely decision-making regarding treatment and infection control.

Non-contractual visuals / Product not CE marked

Future panels

MagIA’s generic approach allows for the development of countless immunoassays. Our roadmap includes:

STI panel completion:

As a frequent coinfection of HIV and a re-emerging disease, we consider adding syphilis to our STI panel. We also consider completing the panel with p24 for early HIV detection.

Hepatitis B:

By detecting HBsAg as well as anti-HBs and anti-HBc antibodies, the HepB test will enable to make a rapid decision for patient vaccination or treatment.

Tropical fever:

A tropical fever test will allow the parallel detection of Dengue fever, Chikungunya and Zika.

MagIA’s generic approach allows for the development of countless immunoassays. Our roadmap includes:

STI panel completion:

As a frequent coinfection of HIV and a re-emerging disease, we consider adding syphilis to our STI panel. We also consider completing the panel with p24 for early HIV detection.

Hepatitis B:

By detecting HBsAg as well as anti-HBs and anti-HBc antibodies, the HepB test will enable to make a rapid decision for patient vaccination or treatment.

Tropical fever:

A tropical fever test will allow the parallel detection of Dengue fever, Chikungunya and Zika.

Download our

brochure here

+ 33 4 76 75 46 00

2017-2024 MagIA Diagnostics

Home

Diagnostics

Life sciences

About us

Contact us

News

Legal Notice

Cookies policy

Log in

+ 33 4 76 75 46 00 

2017-2024 MagIA Diagnostics

Home

Diagnostics

Life sciences

About us

Contact us

News

Legal Notice

Cookies policy

Log in

+ 33 4 76 75 46 00 

2017-2024 MagIA Diagnostics

Home

Diagnostics

Life sciences

About us

Contact us

News

Legal Notice

Cookies policy

Log in

Legal Notice

Cookies policy

+ 33 4 76 75 46 00 

contact@magia-diagnostics.com

2017-2024 MagIA Diagnostics